钙调神经磷酸酶抑制剂治疗足细胞基因变异所致肾病综合征的多中心回顾性研究
该多中心回顾性研究纳入37个儿童肾脏病中心的203例0-18岁单基因型激素抵抗型肾病综合征(SRNS)患儿,其中122例为致病性变异、19例为可能致病性变异,评估钙调神经磷酸酶抑制剂(CNI)治疗至少3个月的缓解率、缓解预测因素及肾功能结局。治疗6个月时27.6%、末次随访时22.5%的患者达到部分或完全缓解;6个月时至少部分缓解者末次随访肾衰竭风险显著低于无缓解者(HR 0.25,95%CI 0.10-0.62)。
要点
- 单基因型SRNS患儿接受CNI治疗6个月时27.6%达部分或完全缓解,末次随访时22.5%达缓解。
- 6个月时至少部分缓解者末次随访肾衰竭风险显著低于无缓解者(HR 0.25,95%CI 0.10-0.62)。
- CNI起始时血清白蛋白较高与6个月时显著缓解可能性增加相关(OR 1.16,95%CI 1.08-1.24)。
核心结论
- 研究结果支持在单基因型SRNS患儿中也进行CNI治疗试验。
研究设计与样本
- 多中心回顾性研究,数据来自37个儿童肾脏病中心,共203例0-18岁单基因型SRNS患儿接受CNI治疗至少3个月。
- 变异致病性经遗传学家审核,122例为致病性变异、19例为可能致病性变异并纳入分析。
主要发现
- 治疗6个月时27.6%的患者、末次随访时22.5%的患者达到部分或完全缓解。
- 6个月时至少部分缓解者末次随访肾衰竭风险显著低于无缓解者(HR 0.25,95%CI 0.10-0.62)。
- 仅纳入随访超过2年的患者时,肾衰竭风险仍显著较低(HR 0.35,95%CI 0.14-0.91)。
- CNI起始时血清白蛋白较高是6个月时显著缓解可能性增加的唯一相关因素(OR 1.16,95%CI 1.08-1.24)。
临床怎么用
- 作者认为研究结果支持在单基因型SRNS患儿中也进行CNI治疗试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While 44-83% of children with steroid-resistant nephrotic syndrome (SRNS) without a proven genetic cause respond to treatment with a calcineurin inhibitor (CNI), current guidelines recommend against the use of immunosuppression in monogenic SRNS. This is despite existing evidence suggesting that remission with CNI treatment is possible and can improve prognosis in some cases of monogenic SRNS. Herein, our retrospective study assessed response frequency, predictors of response and kidney function outcomes among children with monogenic SRNS treated with a CNI for at least three months. Data from 203 cases (age 0-18 years) were collected from 37 pediatric nephrology centers. Variant pathogenicity was reviewed by a geneticist, and 122 patients with a pathogenic and 19 with a possible pathogenic genotype were included in the analysis. After six months of treatment and at last visit, 27.6% and 22.5% of all patients respectively, demonstrated partial or full response. Achievement of at least partial response at six months of treatment conferred a significant reduction in kidney failure risk at last follow-up compared to no response (hazard ratio [95% confidence interval] 0.25, [0.10-0.62]). Moreover, risk of kidney failure was significantly lower when only those with a follow-up longer than two years were considered (hazard ratio 0.35, [0.14-0.91]). Higher serum albumin level at CNI initiation was the only factor related to increased likelihood of significant remission at six months (odds ratio [95% confidence interval] 1.16, [1.08-1.24]). Thus, our findings justify a treatment trial with a CNI also in children with monogenic SRNS.
引用
- Malakasioti G, Iancu D, Milovanova A, et al. A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants. Kidney Int. 2023. PMID: 36898413. doi:10.1016/j.kint.2023.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。